What is needed to get Australians vaccinated by December? Completing the vaccination program in 2021 is plausible, but GPs say additional funding and delivering mRNA vaccines will be crucial to utilising general practice’s ‘untapped capacity’.
Evidence suggests AstraZeneca and Pfizer are equally effective Experts say the research is reassuring, and indicates that both COVID vaccines offer a pathway to Australia reaching a high level of immunity.
Promise wanes for mRNA onshore production With local manufacturing of mRNA vaccines looking increasingly slim in the short term, where does that leave Australia?
AstraZeneca and Pfizer: What are the side effects of Australia’s vaccines? People under 55, women and those previously infected with COVID-19 are more likely to report side effects after receiving either vaccine, according to new research.
GPs with AstraZeneca stockpile turn attention to vaccinating over-50s Patient concerns around the AstraZeneca vaccine have seen a decline in interest in some practices, prompting GPs to bring forward the new rollout strategy’s commencement date.
Benefits of AstraZeneca overwhelmingly high despite increased clotting risk New European research has found the risk of a rare blood clotting syndrome associated with the vaccine is double what has been previously reported.
The world wants mRNA vaccines – but we’re short of vital components Given AstraZeneca is no longer recommended for under-50s, Australia is looking to other vaccines to fill the gap.
Growing number of Australians reject COVID vaccination Vaccine hesitancy has soared since recommendations shifted from AstraZeneca to Pfizer for under-50s.
GPs set to receive more AstraZeneca doses in fast-tracked rollout The shift means people over 50 will have access to COVID vaccines from GP respiratory clinics from 3 May, and general practices from 17 May.
Blood clot case under investigation following Pfizer vaccine The news comes as Australia moves to establish local mRNA manufacturing capacity and experts call for current Pfizer supplies to be redirected to younger cohorts.